Ionis Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Ionis Pharmaceuticals' El consejero delegado es Brett Monia , nombrado en Jan 2020, tiene un mandato de 3.92 años. la remuneración anual total es $7.30M , compuesta por 11.3% salario y 88.7% primas, incluidas acciones y opciones de la empresa. posee directamente 0.082% de las acciones de la empresa, por valor de $5.81M . La antigüedad media del equipo directivo y del consejo de administración es de 3.9 años y 9.8 años respectivamente.

Información clave

Brett Monia

Chief Executive Officer (CEO)

US$7.3m

Compensación total

Porcentaje del salario del CEO	11.3%
Permanencia del CEO	4.3yrs
Participación del CEO	0.1%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	7.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Brett Monia en comparación con los beneficios de Ionis Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$366m
Sep 30 2023	n/a	n/a	-US$409m
Jun 30 2023	n/a	n/a	-US$309m
Mar 31 2023	n/a	n/a	-US$329m
Dec 31 2022	US$7m	US$825k	-US$270m
Sep 30 2022	n/a	n/a	US$7m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$4m
Dec 31 2021	US$13m	US$800k	-US$29m
Sep 30 2021	n/a	n/a	-US$608m
Jun 30 2021	n/a	n/a	-US$550m
Mar 31 2021	n/a	n/a	-US$495m
Dec 31 2020	US$11m	US$700k	-US$444m
Sep 30 2020	n/a	n/a	US$94m
Jun 30 2020	n/a	n/a	US$145m
Mar 31 2020	n/a	n/a	US$169m
Dec 31 2019	US$7m	US$528k	US$281m
Sep 30 2019	n/a	n/a	US$433m
Jun 30 2019	n/a	n/a	US$402m
Mar 31 2019	n/a	n/a	US$366m
Dec 31 2018	US$4m	US$508k	US$277m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	-US$38m
Mar 31 2018	n/a	n/a	US$9m
Dec 31 2017	US$2m	US$443k	US$19m

Compensación vs. Mercado: Brett($USD7.30M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD3.15M).

Compensación vs. Ingresos: La compensación de Brett ha sido consistente con los resultados de la empresa en el último año.

CEO

Brett Monia (62 yo)

4.3yrs

Permanencia

US$7,299,077

Compensación

Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Brett Monia	Founder	4.3yrs	US$7.30m	0.12% $ 7.1m
Elizabeth Hougen	Executive VP of Finance & CFO	11.3yrs	US$2.49m	0.064% $ 3.8m
B. Parshall	Senior Strategic Advisor & Director	6.3yrs	US$812.34k	0.057% $ 3.4m
Richard Geary	Executive VP & Chief Development Officer	15.7yrs	US$2.31m	0.060% $ 3.6m
Joseph Baroldi	Executive VP & Chief Business Officer	2.3yrs	US$4.06m	0.0099% $ 590.9k
Darren Gonzales	Chief Accounting Officer & Senior VP	4.2yrs	sin datos	sin datos
C. Bennett	Executive VP & Chief Scientific Officer	4.3yrs	US$958.87k	0.055% $ 3.3m
D. Walke	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Patrick O'Neil	Executive VP	11.3yrs	US$3.92m	0.033% $ 2.0m
Hayley Soffer	Vice President of Corporate Communications	less than a year	sin datos	sin datos
Shannon Devers	Senior Vice President of Human Resources	4.2yrs	sin datos	sin datos
Stanley Crooke	Scientific Advisor	2.8yrs	US$2.28m	sin datos

4.3yrs

Permanencia media

63.5yo

Promedio de edad

Equipo directivo experimentado: 0JDIEl equipo directivo de la empresa se considera experimentado (3.9 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Brett Monia	Founder	5.1yrs	US$7.30m	0.12% $ 7.1m
B. Parshall	Senior Strategic Advisor & Director	23.6yrs	US$812.34k	0.057% $ 3.4m
Joan Herman	Independent Director	4.8yrs	US$562.20k	0.026% $ 1.5m
Joseph Klein	Independent Director	18.3yrs	US$592.84k	0.015% $ 918.3k
Joseph Wender	Lead Independent Director	30.3yrs	US$627.70k	0.077% $ 4.6m
Michael Hayden	Independent Director	5.6yrs	US$575.84k	0.022% $ 1.3m
Spencer Berthelsen	Independent Director	21.9yrs	US$577.70k	0.10% $ 6.0m
Joseph Loscalzo	Independent Chairman of the Board	10.2yrs	US$597.70k	0.028% $ 1.7m
Allene Diaz	Independent Director	2.8yrs	US$569.74k	0.0087% $ 518.8k
Michael Yang	Director	less than a year	sin datos	sin datos

7.9yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de 0JDI se considera experimentada (9.8 años de antigüedad promedio).

Ionis Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Founder recently sold US$1.0m worth of stock

Insufficient new directors

Insufficient new directors

Recent updates

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$1.90 loss in FY 2022)

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$1.03 loss per share (vs US$0.33 loss in 3Q 2022)

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.74 loss in 2Q 2022)

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

First quarter 2023 earnings released: US$0.87 loss per share (vs US$0.46 loss in 1Q 2022)

Full year 2022 earnings released: US$1.90 loss per share (vs US$0.20 loss in FY 2021)

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.58 loss in 3Q 2021)

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.64 loss in 1Q 2021)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Ionis and Astrazeneca Announce Positive Data for Etesian Phase 2B Study of Antisense Medicine Targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Biogen Inc. and Ionis Pharmaceuticals, Inc. Announce Topline Phase 1 Study Results of BIIB078 in C9orf72 Amyotrophic Lateral Sclerosis

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ionis Pharmaceuticals, Inc. Announce Discontinuation of Vupanorsen Clinical Development Program

Ionis Pharmaceuticals, Inc. Announces eplontersen Receives Orphan Drug Designation from U.S. FDA

Independent Director Peter Reikes has left the company

Ionis Announces That Pfizer Reports Topline Results from Phase 2B Clinical Study of Vupanorsen

Third quarter 2021 earnings released: US$0.58 loss per share (vs US$0.22 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.23 loss in 2Q 2020)

Ionis Pharmaceuticals, Inc. Continues to Advance in the Clinic as the Potential First-In-Class Treatment for Lipoprotein(a) or Lp(a)-Driven Cardiovascular Disease

High number of new directors

Independent Director Breaux Castleman has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.35 loss in 1Q 2020)

Full year 2020 earnings released: US$3.22 loss per share (vs US$2.12 profit in FY 2019)

Revenue beats expectations

Ionis Pharmaceuticals, Inc. Appoints Eugene Schneider as Executive Vice President and Chief Clinical Development Officer

Stanley T. Crooke to Retire from Ionis Pharmaceuticals, Inc. as Executive Chairman

Ionis Pharmaceuticals, Inc. Announces Initiation of Global Phase 3 BALANCE Study for AKCEA-APOCIII-LRX in Patients with Familial Chylomicronemia Syndrome